Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26811032 | 0.82 | TSHR (0.50) | — | |
| SCHEMBL26807881 | 0.82 | TGFBR1 (0.49) | TGFBR1 | |
| SCHEMBL26811002 | 0.81 | TSHR (0.46) | — | |
| SCHEMBL26811019 | 0.80 | GRM1 (0.49) | TGFBR1 | |
| SCHEMBL26811003 | 0.80 | TSHR (0.48) | — | |
| SCHEMBL26811034 | 0.80 | TSHR (0.47) | — | |
| SCHEMBL24309955 | 0.78 | TSHR (0.46) | — | |
| SCHEMBL26811036 | 0.78 | TSHR (0.46) | — | |
| SCHEMBL26865625 | 0.78 | TSHR (0.46) | PRMT5 | |
| SCHEMBL26810991 | 0.77 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TGFBR1 554/4885LIMK2 3726/4885STS 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.